The development of the anti-migraine therapeutics, triptans-5-HT 1B/1D ... the trigeminal nucleus caudalis and the C1 and C2 regions of the spinal cord, collectively known as the trigeminocervical ...

The combined company, which will operate under the Oruka Therapeutics banner and trade on the Nasdaq ... and Recombinant Nematode Anticoagulant Protein c2 (“rNAPc2”),” Arca revealed in its earnings ...

It also reviews key players involved in Semaphorin 3A targeted therapeutics development with respective active ... This gene is a member of the semaphorin family and encodes a protein with an Ig-like ...

Complement biomarker analysis in ocular fluid samples from subjects with geographic atrophy (GA) in a Phase I/II clinical trial of subretinal AAV2 complement factor I (CFI; FI) gene therapy, PPY988 ...

GC Therapeutics, Inc. (GCTx), announced its launch today to scale and unlock the next generation of cell therapy. Invented and developed by a world-class team of scientists in the lab of professor ...

We came across a bullish thesis on TG Therapeutics Inc (TGTX) on ValueInvestorsClub by Bohr. In this article we will summarize the bulls' thesis on TGTX. TG Therapeutics shares were trading at $14 ...

PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by ...

Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment ...

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Liisa Bayko from Evercore ISI maintained a Buy rating on the ...

Sorrento Therapeutics faced a financial and legal crisis in February 2023, and needed to file for bankruptcy. The pharmaceutical developer’s chief executive and chief financial officers met with ...